drugset / Trial / NCT04696705
Allogeneic γδ T Cells Immunotherapy in r/r Non-Hodgkin's Lymphoma (NHL) or Peripheral T Cell Lymphomas (PTCL) Patients
Phase 0
Unknown
10 enrolled
Institute of Hematology & Blood Diseases Hospital, China
Beijing GD Initiative Cell Therapy Technology Co., Ltd. · collabChinese Academy of Medical Sciences · collab
NaSingle-groupOpen-labelTreatment
Summary
This study aims to evaluate the safety, tolerability and efficacy of ex-vivo expanded allogeneic γδT cells obtained from a blood-related donor of patients with relapsed or refractory B cell non-Hodgkin's lymphoma (B-NHL) or peripheral T cell lymphoma (PTCL) expect for γδT lymphoma.
Timeline
- Start
- 2020-12-31
- Primary completion
- 2021-12-25
- Completion
- 2023-12-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ex-vivo expanded allogeneic γδT cells | Cell therapy | 1e+07 cells/kg | — |
| Subject | Ex-vivo expanded allogeneic γδT cells | Cell therapy | 3e+07 cells/kg | — |
| Subject | Ex-vivo expanded allogeneic γδT cells | Cell therapy | 9e+07 cells/kg | — |